Claims for Patent: 8,333,963

✉ Email this page to a colleague

Summary for Patent: 8,333,963

Title:	Method of inhibiting osteoclast activity
Abstract:	Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer.
Inventor(s):	Anderson; Dirk M (Port Townsend, WA), Galibert; Laurent J (Prevessin Moens, FR)
Assignee:	Immunex Corporation (Thousand Oaks, CA)
Application Number:	12/850,368
Patent Claims:	1. A method of inhibiting RANK-induced osteoclastogenesis in a patient in need thereof, comprising administering to the patient an antagonistic antibody that binds a RANKL polypeptide consisting of SEQ ID NO:8, wherein the patient suffers from a condition selected from the group consisting of bone cancer, multiple myeloma, melanoma and breast cancer, and the antibody is administered in an amount sufficient to inhibit RANK-induced osteoclastogenesis in the patient. 2. The method of claim 1, wherein the patient suffers from multiple myeloma. 3. The method of claim 1, wherein the patient suffers from breast cancer. 4. A method of inhibiting RANK-induced osteoclastogenesis in a patient in need thereof, the method comprising administering to the patient an antagonistic antibody that binds a RANKL polypeptide consisting of SEQ ID NO:8, wherein the patient suffers from a condition selected from the group consisting of squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancer, head and neck cancer and renal cancer, and the antibody is administered in an amount sufficient to inhibit RANK-induced osteoclastogenesis in the patient. 5. The method of claim 4, wherein the patient suffers from prostate cancer. 6. The method of claim 4, wherein the patient suffers from lung cancer. 7. The method of claim 4, wherein the patient suffers from squamous cell carcinoma.

Details for Patent 8,333,963

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	PROLIA	denosumab	Injection	125320	June 01, 2010	8,333,963	2016-12-23
Amgen Inc.	XGEVA	denosumab	Injection	125320	November 18, 2010	8,333,963	2016-12-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,333,963

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9958674	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9828426	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9828424	⤷ Subscribe
United States of America	8715683	⤷ Subscribe
United States of America	8569456	⤷ Subscribe
United States of America	8377690	⤷ Subscribe
United States of America	8153775	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.